[ninja_forms id=112]
Register »INQOVI® (decitabine and cedazuridine) 35mg/100mg tablets Indications and Important Safety Information
[ninja_forms id=101] INDICATIONS INQOVI is indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, …
Register »2020 AZ BRCA Dinners
[ninja_forms id=83] This program is intended for US healthcare professionals only. AstraZeneca will comply with any and all federal or state reporting requirements regarding any value or expense associated with this event. AstraZeneca fully supports and abides by the PhRMA Code on Interactions With Health Care Professionals (HCPs). This program …
Register »FASLODEX® (fulvestrant) Injection 2018 Registration
[ninja_forms id=79] FASLODEX is a registered trademark of the AstraZeneca group of companies. ©2018 AstraZeneca. All rights reserved. US-24395 Last Updated 10/18
Register »